Project Grant R01HL170175
Award Date 9/15/25
Completion Date 6/30/30
Dollars Obligated $674K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to advance precision medicine for Acute Respiratory Distress Syndrome (ARDS) and sepsis. The $2,295,984 award to the University of California, San Francisco (UCSF) will fund research to address critical unanswered questions about the distinct molecular phenotypes of ARDS and sepsis, and how to optimize real-time phenotyping and integrate analyses of phenotype-specific...
- This federal Project Grant award of $1,479,335.00 from the National Heart Lung and Blood Institute under CFDA 93.837 Cardiovascular Diseases Research aims to leverage observational data and advanced machine learning methods to address gaps in understanding and personalizing treatment for Acute Respiratory Distress Syndrome (ARDS). The key products and services to be delivered include: Developing improved methods for ARDS phenotyping using dynamic clinical data to better understand prognosis...
- This federal Project Grant award of $200,502 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research project led by Dr. Narges Alipanah-Lechner at the University of California, San Francisco (UCSF). The project aims to identify metabolite and protein drivers of the evolution of Acute Respiratory Distress Syndrome (ARDS) subtypes, specifically the hyper-inflammatory and hypo-inflammatory forms. The research will utilize comprehensive...
- This $775,992 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research by the University of North Carolina at Chapel Hill to investigate the role of regulatory T cells and glucocorticoids in the resolution of acute lung injury and acute respiratory distress syndrome (ARDS). The research aims to determine how glucocorticoid signaling through regulatory T cells impacts the recovery of lung structure and function following...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, is focused on studying the role of indole metabolites as danger signals in the pathogenesis of acute respiratory distress syndrome (ARDS). The $688,163 award to the University of Pittsburgh covers the period from Sep 1, 2025 to May 31, 2029. The research aims to investigate how microbial-derived indole metabolites activate regulated cell death...
- This $607,952 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pittsburgh to investigate indole metabolites as novel danger signals that activate regulated cell death pathways in lung epithelial cells, which may contribute to the pathogenesis of acute respiratory distress syndrome (ARDS). The key research objectives include...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $737,815 to The Washington University in St. Louis to develop and validate an automated electronic health record (EHR)-embedded system that can classify molecular phenotypes of acute respiratory distress syndrome (ARDS) and sepsis at the bedside. The primary objective is to translate advanced research on ARDS and sepsis heterogeneity into clinical...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $791,503 to Weill Medical College of Cornell University to conduct research on the role of the thrombin receptor protease activated receptor-1 (PAR1) in lung lymphatic function and acute respiratory distress syndrome (ARDS). The 4-year award, effective September 15, 2025, aims to investigate a previously unappreciated function of PAR1 in the lung lymphatic...
- This $761,615 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the role of biological sex in the heterogeneity of Acute Respiratory Distress Syndrome (ARDS). The research team at Massachusetts General Hospital aims to determine how increased alveolar epithelial expression of Secretory Leukocyte Protease Inhibitor (SLPI) in females may increase epithelial glycocalyx resilience, leading to a...
- This Project Grant award of $153,099.00 from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) is funding research to use target trial emulation and g-methods for causal inference from observational data to address gaps in knowledge about the care of patients with acute respiratory distress syndrome (ARDS), with a focus on evaluating dynamic treatment regimes for steroid initiation, duration, and dosing. The research will utilize data...